Evidence map›Paper›PMID 25702088›Full record

ReviewVirology2015

Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.

Christian K Pfaller, Roberto Cattaneo, Matthias J Schnell

Abstract readReview
In one paragraph

Review in Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Negative-Strand RNA Virus-Vectored Vaccines.Methods in molecular biology (Clifton, N.J.) · 2024
    Review
  7. Article
  8. Recombinant Cedar Virus: A Henipavirus Reverse Genetics Platform.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. A Novel Anphevirus inViruses · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christian K PfallerDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Roberto CattaneoDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: Cattaneo.Roberto@mayo.edu.
Matthias J SchnellDepartment of Microbiology and Immunology, Philadelphia, PA 19107, USA; Jefferson Vaccine Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address: Matthias.schnell@jefferson.edu.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
CENTER FOR NEUROANATOMY WITH NEUROTROPIC VIRUSES: COMPARATIVE MEDICINEP40RR018604 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STRICK, PETER · 2004 to 2011
$6.5M
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccineR01AI105204 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI SCHNELL, MATTHIAS JOHANNES · 2013 to 2017
$5.0M
Immunosuppression and Innate Immunity Control by MorbillivirusesR01AI063476 · NIAID · MAYO CLINIC ROCHESTER · PI CATTANEO, ROBERTO B. · 2005 to 2014
$3.2M
A novel vaccine: botulinum neurotoxin subunit on a viral carrier.R42AI073064 · NIAID · MOLECULAR TARGETING TECHNOLOGIES, INC. · PI SCHNELL, MATTHIAS JOHANNES · 2012 to 2014
$2.5M
Lymphoma Therapy with Reprogrammed Measles VirusesR01CA139389 · NCI · MAYO CLINIC ROCHESTER · PI CATTANEO, ROBERTO B. · 2010 to 2013
$1.2M
Fate of neurons following immune-mediated viral clearanceR21NS074006 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI RALL, GLENN F, SCHNELL, MATTHIAS JOHANNES · 2011 to 2012
$467k
Tailored Intervention Protocol for Oral Chemotherapy AdherenceR15CA139398 · NCI · DUKE UNIVERSITY · PI SCHNEIDER, SUSAN M. · 2009 to 2009
$234k
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA139389NCI NIH HHS R01CA139398NCI NIH HHS R15 CA139398NCRR NIH HHS P40 RR018604NCRR NIH HHS P40RR018604NIAID NIH HHS R01 AI063476NIAID NIH HHS R01AI063476NIAID NIH HHS R01 AI105204NIAID NIH HHS R01AI105204NIAID NIH HHS R42 AI073064NIAID NIH HHS R42AI073064NINDS NIH HHS R21 NS074006NINDS NIH HHS R21NS074006
6 · The paper itself

Abstract

The order Mononegavirales includes five families: Bornaviridae, Filoviridae, Nyamaviridae, Paramyxoviridae, and Rhabdoviridae. The genome of these viruses is one molecule of negative-sense single strand RNA coding for five to ten genes in a conserved order. The RNA is not infectious until packaged by the nucleocapsid protein and transcribed by the polymerase and co-factors. Reverse genetics approaches have answered fundamental questions about the biology of Mononegavirales. The lack of icosahedral symmetry and modular organization in the genome of these viruses has facilitated engineering of viruses expressing fluorescent proteins, and these fluorescent proteins have provided important insights about the molecular and cellular basis of tissue tropism and pathogenesis. Studies have assessed the relevance for virulence of different receptors and the interactions with cellular proteins governing the innate immune responses. Research has also analyzed the mechanisms of attenuation. Based on these findings, ongoing clinical trials are exploring new live attenuated vaccines and the use of viruses re-engineered as cancer therapeutics.

Indexed as

Reverse GeneticsHost-Pathogen InteractionsHumansMononegaviralesNeoplasmsOncolytic VirotherapyVaccines, AttenuatedViral TropismViral VaccinesVirus AssemblyVirus ReplicationVaccines, AttenuatedViral VaccinesAttenuationCancer therapyInnate immunityMononegaviralesPathologyReceptorsReverse geneticsTropismVaccines

Identifiers

PMID25702088
PMCPMC4557643

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.